{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:38Z","timestamp":1794047438994,"version":"4.8.0"},"reference-count":60,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"1","license":[{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>CD40 signaling upregulates BCL-XL and MCL-1 expression in the chronic lymphocytic leukemia (CLL) lymph node microenvironment, affording resistance to the BCL-2 inhibitor, venetoclax. Venetoclax resistance in the therapeutic setting and after long-term laboratory selection has been linked to metabolic alterations, but the underlying mechanism(s) are unknown. We aimed here to discover how CD40 stimulation as a model for tumor microenvironment-mediated metabolic changes, affects venetoclax sensitivity\/resistance. CD40 stimulation increased oxidative phosphorylation and glycolysis, but only inhibition of oxidative phosphorylation countered venetoclax resistance. Furthermore, blocking mitochondrial import of pyruvate, glutamine or fatty acids affected CLL metabolism, but did not prevent CD40-mediated resistance to venetoclax. In contrast, inhibition of the electron transport chain (ETC) at complex I, III or V attenuated CLL activation and ATP production, and downregulated MCL-1 and BCL-XL, correlating with reduced CD40 surface expression. Moreover, ETC inhibition equaled mTOR1\/2 but not mTOR1 inhibition alone for venetoclax resistance, and all three pathways were linked to control of general protein translation. In line with this, ETC plus mTOR inhibition synergistically counteracted venetoclax resistance. These findings link oxidative CLL metabolism to CD40 expression and cellular signaling, and may hold clinical potential.<\/jats:p>","DOI":"10.3324\/haematol.2023.282760","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T04:00:02Z","timestamp":1689220802000},"page":"151-162","source":"Crossref","is-referenced-by-count":8,"title":["Electron transport chain and mTOR inhibition synergistically decrease CD40 signaling and counteract venetoclax resistance in chronic lymphocytic leukemia"],"prefix":"10.3324","volume":"109","author":[{"given":"Zhenghao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaspard","family":"Cretenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Carnazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga","family":"Simon-Molas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon P.","family":"Kater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerritje J. W. van der","family":"Windt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Eldering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"key":"56169","doi-asserted-by":"crossref","unstructured":"Chiorazzi N, Chen SS, Rai KR. Chronic lymphocytic leukemia. Cold Spring Harb Perspect Med. 2021; 11(2):1-35.","DOI":"10.1101\/cshperspect.a035220"},{"key":"56170","doi-asserted-by":"crossref","unstructured":"ten Hacken E, Burger JA. Microenvironment dependency in chronic lymphocytic leukemia: the basis for new targeted therapies. Pharmacol Ther. 2014; 144(3):338-348.","DOI":"10.1016\/j.pharmthera.2014.07.003"},{"key":"56171","doi-asserted-by":"crossref","unstructured":"Burger JA. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2011; 2011(1):96-103.","DOI":"10.1182\/asheducation-2011.1.96"},{"key":"56172","doi-asserted-by":"crossref","unstructured":"Haselager M, Thijssen R, West C. Regulation of Bcl-XL by non-canonical NF-\u03baB in the context of CD40-induced drug resistance in CLL. Cell Death Differ. 2021; 28(5):1658-1668.","DOI":"10.1038\/s41418-020-00692-w"},{"key":"56173","doi-asserted-by":"crossref","unstructured":"ten Hacken E, Burger JA. Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia-focus on the B-cell receptor. Clin Cancer Res. 2014; 20(3):548-556.","DOI":"10.1158\/1078-0432.CCR-13-0226"},{"key":"56174","doi-asserted-by":"crossref","unstructured":"Kennedy E, Coulter E, Halliwell E. TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. Blood. 2021; 137(22):3064-3078.","DOI":"10.1182\/blood.2020005964"},{"key":"56175","doi-asserted-by":"crossref","unstructured":"Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol. 1996; 92(1):97-103.","DOI":"10.1046\/j.1365-2141.1996.00305.x"},{"key":"56176","doi-asserted-by":"crossref","unstructured":"Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell\u2019Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000; 96(8):2655-2663.","DOI":"10.1182\/blood.V96.8.2655"},{"key":"56177","doi-asserted-by":"crossref","unstructured":"Ghia P, Strola G, Granziero L. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+,CD40L+ T cells by producing CCL22. Eur J Immunol. 2002; 32(5):1403-1413.","DOI":"10.1002\/1521-4141(200205)32:5<1403::AID-IMMU1403>3.0.CO;2-Y"},{"key":"56178","doi-asserted-by":"crossref","unstructured":"Burger JA, Gandhi V. The lymphatic tissue microenvironments in chronic lymphocytic leukemia: in vitro models and the significance of CD40-CD154 interactions. Blood. 2009; 114(12):2560-2561.","DOI":"10.1182\/blood-2009-06-228981"},{"key":"56179","doi-asserted-by":"crossref","unstructured":"Kurtova AV, Balakrishnan K, Chen R. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009; 114(20):4441-4450.","DOI":"10.1182\/blood-2009-07-233718"},{"key":"56180","doi-asserted-by":"crossref","unstructured":"Smit LA, Hallaert DYH, Spijker R. Differential Noxa\/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood. 2007; 109(4):1660-1668.","DOI":"10.1182\/blood-2006-05-021683"},{"key":"56181","doi-asserted-by":"crossref","unstructured":"Thijssen R, Slinger E, Weller K. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica. 2015; 100(8):e302-306.","DOI":"10.3324\/haematol.2015.124560"},{"key":"56182","doi-asserted-by":"crossref","unstructured":"Haselager MV., Kielbassa K, ter Burg J. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. Blood. 2020; 136(25):2918-2926.","DOI":"10.1182\/blood.2019004326"},{"key":"56183","doi-asserted-by":"crossref","unstructured":"Seymour JF, Kipps TJ, Eichhorst B. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018; 378(12):1107-1120.","DOI":"10.1056\/NEJMoa1713976"},{"key":"56184","doi-asserted-by":"crossref","unstructured":"Roberts AW, Davids MS, Pagel JM. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016; 374(4):311-322.","DOI":"10.1056\/NEJMoa1513257"},{"key":"56185","doi-asserted-by":"crossref","unstructured":"Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019; 94(11):1266-1287.","DOI":"10.1002\/ajh.25595"},{"key":"56186","unstructured":"Gui\u00e8ze R, Liu VM, Rosebrock D. Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies. Cancer Cell. 2019; 36(4):369-384.e13."},{"key":"56187","doi-asserted-by":"crossref","unstructured":"Roca-Portoles A, Rodriguez-Blanco G, Sumpton D. Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition. Cell Death Dis. 2020; 11(8):616.","DOI":"10.1038\/s41419-020-02867-2"},{"key":"56188","doi-asserted-by":"crossref","unstructured":"Thomalla D, Beckmann L, Grimm C. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood. 2022; 140(20):2113-2126.","DOI":"10.1182\/blood.2021014304"},{"key":"56189","doi-asserted-by":"crossref","unstructured":"Warburg O. On the origin of cancer cells. Science. 1956; 123(3191):309-314.","DOI":"10.1126\/science.123.3191.309"},{"key":"56190","doi-asserted-by":"crossref","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-674.","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"56191","doi-asserted-by":"crossref","unstructured":"Jitschin R, Hofmann AD, Bruns H. Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. Blood. 2014; 123(17):2663-2672.","DOI":"10.1182\/blood-2013-10-532200"},{"key":"56192","doi-asserted-by":"crossref","unstructured":"Chen Z, Simon-Molas H, Cretenet G. Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment. Blood. 2022; 140(6):630-643.","DOI":"10.1182\/blood.2021013990"},{"key":"56193","doi-asserted-by":"crossref","unstructured":"Zheng J. Energy metabolism of cancer: glycolysis versus oxidative phosphorylation (review). Oncol Lett. 2012; 4(6):1151-1157.","DOI":"10.3892\/ol.2012.928"},{"key":"56194","doi-asserted-by":"crossref","unstructured":"Ashton TM, Gillies McKenna W, Kunz-Schughart LA, Higgins GS. Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res. 2018; 24(11):2482-2490.","DOI":"10.1158\/1078-0432.CCR-17-3070"},{"key":"56195","doi-asserted-by":"crossref","unstructured":"Farge T, Saland E, de Toni F. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 2017; 7(7):716-735.","DOI":"10.1158\/2159-8290.CD-16-0441"},{"key":"56196","doi-asserted-by":"crossref","unstructured":"Vyas S, Zaganjor E, Haigis MC. Mitochondria and cancer. Cell. 2016; 166(3):555-566.","DOI":"10.1016\/j.cell.2016.07.002"},{"key":"56197","doi-asserted-by":"crossref","unstructured":"Schiliro C, Firestein BL. Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation. Cells. 2021; 10(5):1056.","DOI":"10.3390\/cells10051056"},{"key":"56198","doi-asserted-by":"crossref","unstructured":"Van Attekum MHA, Terpstra S, Slinger E. Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia. Oncogene. 2017; 36(26):3651-3660.","DOI":"10.1038\/onc.2016.515"},{"key":"56199","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Reyes I, Diebold LP, Kong H. TCA cycle and mitochondrial membrane potential are necessary for diverse biological functions. Mol Cell. 2016; 61(2):199-209.","DOI":"10.1016\/j.molcel.2015.12.002"},{"key":"56200","doi-asserted-by":"crossref","unstructured":"Kielbassa K, Haselager MV, Bax DJC. Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation. Leukemia. 2023; 37(6):1268-1276.","DOI":"10.1038\/s41375-023-01898-w"},{"key":"56201","doi-asserted-by":"crossref","unstructured":"van Noorden CJF, Hira VVV, van Dijck AJ, Novak M, Breznik B, Molenaar RJ. Energy metabolism in IDH1 wild\u2010type and IDH1-mutated glioblastoma stem cells: a novel target for therapy?. Cells. 2021; 10(3):1-16.","DOI":"10.3390\/cells10030705"},{"key":"56202","doi-asserted-by":"crossref","unstructured":"Xiao D, Powolny AA, Moura MB. Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive oxygen species-mediated death of human prostate cancer cells. J Biol Chem. 2010; 285(34):26558-26569.","DOI":"10.1074\/jbc.M109.063255"},{"key":"56203","doi-asserted-by":"crossref","unstructured":"Fabbri L, Chakraborty A, Robert C, Vagner S. The plasticity of mRNA translation during cancer progression and therapy resistance. Nat Rev Cancer. 2021; 21(9):558-577.","DOI":"10.1038\/s41568-021-00380-y"},{"key":"56204","doi-asserted-by":"crossref","unstructured":"Blombery P, Thompson ER, Nguyen T. Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. Blood. 2020; 135(10):773-777.","DOI":"10.1182\/blood.2019004205"},{"key":"56205","doi-asserted-by":"crossref","unstructured":"Thijssen R, Tian L, Anderson MA. Single-cell multiomics reveal the scale of multi-layered adaptations enabling CLL relapse during venetoclax therapy. Blood. 2022; 140(20):2127-2141.","DOI":"10.1182\/blood.2022016040"},{"key":"56206","doi-asserted-by":"crossref","unstructured":"Bajpai R, Sharma A, Achreja A. Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. Nat Commun. 2020; 11(1):1228.","DOI":"10.1038\/s41467-020-15051-z"},{"key":"56207","doi-asserted-by":"crossref","unstructured":"Jackson RJ, Hellen CUT, Pestova TV. The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol. 2010; 11(2):113-127.","DOI":"10.1038\/nrm2838"},{"key":"56208","doi-asserted-by":"crossref","unstructured":"Pavitt GD, Ron D. New insights into translational regulation in the endoplasmic reticulum unfolded protein response. Cold Spring Harb Perspect Biol. 2012; 4(6):1-13.","DOI":"10.1101\/cshperspect.a012278"},{"key":"56209","doi-asserted-by":"crossref","unstructured":"Yeomans A, Lemm E, Wilmore S. PEITC-mediated inhibition of mRNA translation is associated with both inhibition of mTORC1 and increased eIF2a phosphorylation in established cell lines and primary human leukemia cells. Oncotarget. 2016; 7(46):74807-74819.","DOI":"10.18632\/oncotarget.11655"},{"key":"56210","doi-asserted-by":"crossref","unstructured":"Wilmore S, Rogers-Broadway KR, Taylor J. Targeted inhibition of eIF4A suppresses B-cell receptor-induced translation and expression of MYC and MCL1 in chronic lymphocytic leukemia cells. Cell Mol Life Sci. 2021; 78(17-18):6337-6349.","DOI":"10.1007\/s00018-021-03910-x"},{"key":"56211","doi-asserted-by":"crossref","unstructured":"Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal. 2009; 2(67)","DOI":"10.1126\/scisignal.267pe24"},{"key":"56212","doi-asserted-by":"crossref","unstructured":"Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol Med. 2007; 13(10):433-442.","DOI":"10.1016\/j.molmed.2007.08.001"},{"key":"56213","doi-asserted-by":"crossref","unstructured":"Kim JY, Jeon JY, Ko YM, Kang MS, Park SK, Roh K. Characteristics of lymphedema in patients treated with mammalian target of rapamycin inhibitors. Lymphat Res Biol. 2021; 19(4):365-371.","DOI":"10.1089\/lrb.2020.0069"},{"key":"56214","doi-asserted-by":"crossref","unstructured":"Bhaoighill MN, Dunlop EA. Mechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeutics. Cancer Drug Resist. 2019; 2(4):1069-1085.","DOI":"10.20517\/cdr.2019.87"},{"key":"56215","doi-asserted-by":"crossref","unstructured":"Brown JR, Chan DK, Shank JJ. Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer. JCI Insight. 2020; 5(11):e133247.","DOI":"10.1172\/jci.insight.133247"},{"key":"56216","doi-asserted-by":"crossref","unstructured":"Goodwin PJ, Parulekar WR, Gelmon KA. Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32. J Natl Cancer Inst. 2015; 107(3):djv006.","DOI":"10.1093\/jnci\/djv006"},{"key":"56217","doi-asserted-by":"crossref","unstructured":"Arrieta O, Barr\u00f3n F, Padilla M-\u00c1S. Effect of metformin plus tyrosine kinase inhibitors compared with tyrosine kinase inhibitors alone in patients with epidermal growth factor receptor-mutated lung adenocarcinoma. JAMA Oncol. 2019; 5(11):e192553.","DOI":"10.1001\/jamaoncol.2019.2553"},{"key":"56218","doi-asserted-by":"crossref","unstructured":"Pollak M. Repurposing biguanides to target energy metabolism for cancer treatment. Nat Med. 2014; 20(6):591-593.","DOI":"10.1038\/nm.3596"},{"key":"56219","doi-asserted-by":"crossref","unstructured":"Molina JR, Sun Y, Protopopova M. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 2018; 24(7):1036-1046.","DOI":"10.1038\/s41591-018-0052-4"},{"key":"56220","doi-asserted-by":"crossref","unstructured":"Liu F, Kalpage HA, Wang D. Cotargeting of mitochondrial complex I and Bcl-2 shows antileukemic activity against acute myeloid leukemia cells reliant on oxidative phosphorylation. Cancers (Basel). 2020; 12(9):2400.","DOI":"10.3390\/cancers12092400"},{"key":"56221","doi-asserted-by":"crossref","unstructured":"Vangapandu HV, Alston B, Morse J. Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells. Oncotarget. 2018; 9(38):24980-24991.","DOI":"10.18632\/oncotarget.25166"},{"key":"56222","doi-asserted-by":"crossref","unstructured":"Alistar AT, Desnoyers R, D\u2019Agostino RJ, Pasche B. CPI-613 enhances FOLFIRINOX response rate in stage IV pancreatic cancer. Ann Oncol. 2016; 27(suppl 6):vi228.","DOI":"10.1093\/annonc\/mdw371.67"},{"key":"56223","doi-asserted-by":"crossref","unstructured":"Pardee TS, Lee K, Luddy J. A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Clin Cancer Res. 2014; 20(20):5255-5264.","DOI":"10.1158\/1078-0432.CCR-14-1019"},{"key":"56224","doi-asserted-by":"crossref","unstructured":"Raczka AM, Reynolds PA. Glutaminase inhibition in renal cell carcinoma therapy. Cancer Drug Resist. 2019; 2(2):356-364.","DOI":"10.20517\/cdr.2018.004"},{"key":"56225","doi-asserted-by":"crossref","unstructured":"Dos Reis LM, Adamoski D, Souza ROO. Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells. J Biol Chem. 2019; 294(24):9342-9357.","DOI":"10.1074\/jbc.RA119.008180"},{"key":"56226","doi-asserted-by":"crossref","unstructured":"Stubbins RJ, Maksakova IA, Sanford DS, Rouhi A, Kuchenbauer F. Mitochondrial metabolism: powering new directions in acute myeloid leukemia. Leuk Lymphoma. 2021; 62(10):2331-2341.","DOI":"10.1080\/10428194.2021.1910685"},{"key":"56227","doi-asserted-by":"crossref","unstructured":"Hege Hurrish K, Su Y, Wiley S. A novel isoflavone, ME-344, enhances venetoclax antileukemic activity against AML via suppression of oxidative phosphorylation and purine biosynthesis. Blood. 2021; 138(Suppl 1):2238.","DOI":"10.1182\/blood-2021-147004"},{"key":"56228","doi-asserted-by":"crossref","unstructured":"Wu D, Smyth GK. CAMERA: a competitive gene set test accounting for inter-gene correlation. Nucleic Acids Res. 2012; 40(17):e133.","DOI":"10.1093\/nar\/gks461"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282760\/75820","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282760\/76433","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11150\/75820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:25Z","timestamp":1794045865000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.282760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,13]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.282760","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,13]]}}}